Kymera Investor Presentation Deck

● As of May 1, 2023, thirteen patients received a mean of five doses across four dose levels. • Tumor types enrolled: CTCL (n=2), PTCL (n=1), and solid tumors (n=10, including colorectal [2], appendiceal, anal, pancreatic, cholangiocarcinoma, peritoneal, endometrial, ovarian and head & neck) Number of Patients with Adverse Event Occurring in ≥2 Patients (n, (%)) Preferred Term Fatigue Anemia Constipation Nausea Dehydration Dizziness Overall Safety Dose Level 1 0.05 mg/kg (n=4) All Related 2 (50) Dose Level 2 0.1 mg/kg (n=4) All Related Dose Level 3 0.2 mg/kg (n=3) All Related KYMERA Ⓒ2023 KYMERA THERAPEUTICS, INC. 1 (25) 2 (50) 2 (50) 1 (25) 1 (25) 1 (25) 1 (25) 1 (25) 1 (25) 1 (25) 1 (25) Skin infection 1 (25) (a) All Grade 1 and 2 events except the following: 1 patient with Gr. 3 abdominal pain and 1 patient with Gr. 3 fatigue that were not related to KT-333. (b) No Grade 4 or Grade 5 events. 1 (33.3) 1 (33.3) 1 (33.3) I Dose Level 4 0.4 mg/kg (n=2c) Related All I I I I Overall a, b (N=13) All 4 (30.8) 3 (23.1) 3 (23.1) 3 (23.1) 2 (15.4) 2 (15.4) 2 (15.4) Relatedd (c) At time of data cut off, DL4 had enrolled two patients and no AEs had been reported. (d) AEs related to KT-333 (n=1 each): Gr. 1: abdominal pain upper, LDH increase, and rash. Gr. 2: diarrhea; hypothyroidism; and squamous cell carcinoma (SCC) of the skin in CTCL patient with history of prior UVB treatment and recurrent skin SCCs considered possibly related. Safety Summary: At the time of the data cut off (May 1, 2023), KT-333 was well tolerated, with no dose limiting toxicity observed and no serious adverse events considered related to KT-333. PAGE 45

View entire presentation